These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Long-term treatment with subcutaneous immunoglobulin in patients with chronic inflammatory demyelinating polyradiculoneuropathy: a follow-up period up to 7 years. Gentile L; Mazzeo A; Russo M; Arimatea I; Vita G; Toscano A Sci Rep; 2020 May; 10(1):7910. PubMed ID: 32404895 [TBL] [Abstract][Full Text] [Related]
11. Comparisons in fluctuation of muscle strength and function in patients with immune-mediated neuropathy treated with intravenous versus subcutaneous immunoglobulin. Christiansen I; Markvardsen LH; Jakobsen J Muscle Nerve; 2018 Apr; 57(4):610-614. PubMed ID: 28881389 [TBL] [Abstract][Full Text] [Related]
12. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial. van Schaik IN; van Geloven N; Bril V; Hartung HP; Lewis RA; Sobue G; Lawo JP; Mielke O; Cornblath DR; Merkies IS; Trials; 2016 Jul; 17(1):345. PubMed ID: 27455854 [TBL] [Abstract][Full Text] [Related]
13. Subcutaneous "bolus" immunoglobulin dose in CIDP: A proof-of concept study. Cocito D; Peci E; Romagnolo A; Rigaldo S; Rosso M; Lopiano L; Merola A J Neurol Sci; 2017 Sep; 380():54-57. PubMed ID: 28870589 [TBL] [Abstract][Full Text] [Related]
14. Changes in axonal and clinical function during intravenous and subcutaneous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy. Hansen PN; Mohammed AA; Markvardsen LK; Andersen H; Tankisi H; Sindrup SH; Krøigård T J Peripher Nerv Syst; 2023 Sep; 28(3):425-435. PubMed ID: 37212187 [TBL] [Abstract][Full Text] [Related]
15. Improvement of hemoglobin levels after a switch from intravenous to subcutaneous administration of immunoglobulin in chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy. Markvardsen LH; Christiansen I; Jakobsen J Transfusion; 2016 Oct; 56(10):2443-2448. PubMed ID: 27401495 [TBL] [Abstract][Full Text] [Related]
16. Validation of the Serbian version of inflammatory Rasch-built overall disability scale in patients with chronic inflammatory demyelinating polyradiculoneuropathy. Peric S; Bozovic I; Pruppers MHJ; Bjelica B; Stevic Z; Faber CG; Merkies ISJ; Basta I J Peripher Nerv Syst; 2019 Sep; 24(3):260-267. PubMed ID: 31397933 [TBL] [Abstract][Full Text] [Related]
17. Subcutaneous immunoglobulin treatment in CIDP and MMN. Efficacy, treatment satisfaction and costs. Markvardsen LH; Harbo T J Neurol Sci; 2017 Jul; 378():19-25. PubMed ID: 28566163 [TBL] [Abstract][Full Text] [Related]
18. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial. van Schaik IN; Bril V; van Geloven N; Hartung HP; Lewis RA; Sobue G; Lawo JP; Praus M; Mielke O; Durn BL; Cornblath DR; Merkies ISJ; Lancet Neurol; 2018 Jan; 17(1):35-46. PubMed ID: 29122523 [TBL] [Abstract][Full Text] [Related]
19. Subcutaneous immunoglobulin infusion: a new therapeutic option in chronic inflammatory demyelinating polyneuropathy. Lee DH; Linker RA; Paulus W; Schneider-Gold C; Chan A; Gold R Muscle Nerve; 2008 Mar; 37(3):406-9. PubMed ID: 17918749 [TBL] [Abstract][Full Text] [Related]
20. Electrophysiological predictors of response to subcutaneous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy. Alcantara M; Hartung HP; Lawo JP; Durn BL; Mielke O; Bril V Clin Neurophysiol; 2021 Sep; 132(9):2184-2190. PubMed ID: 34293528 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]